Welcome to our dedicated page for Prenetics news (Ticker: PRE), a resource for investors and traders seeking the latest updates and insights on Prenetics stock.
Prenetics Global Limited (NASDAQ: PRE) generates an active stream of company news centered on its evolution as a health sciences business and the rapid growth of its IM8 premium health and longevity brand. Press releases describe Prenetics as a leading health sciences company focused on redefining the future of health and longevity through IM8, a premium core nutrition platform co-founded with David Beckham and championed by World No. 1 and four-time Grand Slam winner Aryna Sabalenka.
News updates commonly highlight IM8’s growth milestones, including disclosures that the brand reached over $100 million in annualized recurring revenue within roughly 11 months of launch and has been characterized by the company as the fastest-growing supplement brand in industry history. Articles also cover monthly revenue achievements, subscription metrics, and international expansion, reflecting IM8’s role as the centerpiece of Prenetics’ strategy.
Investors following PRE can also expect news on capital allocation and financing activities. Recent announcements include a best efforts public offering of Class A ordinary shares with accompanying warrants, a voluntary warrant exchange program designed to reduce potential dilution and simplify the capital structure, and updates on the company’s Bitcoin treasury strategy. Prenetics has communicated a shift away from new Bitcoin purchases, choosing instead to maintain existing holdings as a treasury reserve while directing new capital exclusively toward IM8.
Another recurring theme in Prenetics news is strategic portfolio optimization. Releases describe the sale of ACT Genomics, the divestiture of Europa Sports Partners, and an ongoing review of other non-core assets such as CircleDNA and the company’s stake in Insighta. These items are presented as part of a broader effort to focus on IM8 and improve operating margins.
News items may also include earnings announcements, conference participation, and insider share purchases by members of the executive leadership team, which are furnished to the SEC on Form 6-K. For readers tracking PRE, this news page provides a consolidated view of operational updates, financial developments, capital structure changes, and strategic decisions affecting Prenetics and its IM8 brand.
Prenetics (Nasdaq: PRE) announced that its IM8 brand achieved a record $9.0 million in revenue for October 2025, representing 32% month-over-month growth from September's $6.8 million, and reached approximately $108 million in annualized recurring revenue (ARR) 11 months after launch.
Other disclosed metrics: an all-time single-day revenue record of $400,000, average order value rising from ~$110 to $145, 13 million servings delivered to over 420,000 customers across 31 countries, and 80% of new orders via subscription. Prenetics completed a $44 million equity offering to fund global expansion and projects a minimum of $10 million monthly revenue by December 2025, ~$60 million in IM8 revenue for FY2025, and $180–200 million for FY2026.
Prenetics (NASDAQ: PRE) acquired 100 Bitcoin at an average price of $109,594 per BTC, increasing its treasury to 378 BTC (valued at ~$46 million). The purchase was funded as the initial deployment of proceeds from a completed $44 million equity offering that closed on October 28, 2025.
Following the acquisition and financing, Prenetics reports approximately $127 million in total liquidity ($86 million cash and $41 million in Bitcoin) and zero debt. The company also says its IM8 supplement brand reached $100 million ARR within 11 months, with 420,000 customers, ~80% subscription reorder rate, and FY2026 IM8 revenue guidance of $180–$200 million.
Prenetics (NASDAQ: PRE) published a 32-page manifesto titled “The Dual-Engine Revolution” by CEO Danny Yeung outlining a strategy that pairs rapid healthcare growth with a disciplined Bitcoin treasury approach.
Key facts: IM8 reached $100M ARR in 11 months and projects $180–$200M revenue for FY2026. The company holds 277 BTC and adds 1 BTC daily via a stated accumulation strategy. The manifesto is available in multiple formats and links to investor resources and real-time BTC holdings.
Prenetics (NASDAQ: PRE) closed a best-efforts public offering on Oct 28, 2025, selling 2,722,642 Class A ordinary shares and associated Class A and Class B common warrants at a combined price of $16.08 per share with warrants. Gross proceeds were approximately $44.0 million before fees, down from ~$48.0 million previously announced. The Class A warrants carry a $24.12 exercise price (50% premium) and Class B warrants a $32.16 exercise price (100% premium); both are immediately exercisable for five years. The company said proceeds will fund the global expansion of IM8 and strategic accumulation of Bitcoin (BTC). Dominari Securities acted as sole placement agent.
Prenetics (NASDAQ: PRE) priced a public offering to raise approximately $48 million in gross proceeds, plus up to $168 million more if attached Class A and Class B warrants are fully exercised, potentially totaling $216 million. The offering includes double warrants exercisable at $24.12 (50% premium) and $32.16 (100% premium), each expiring in five years.
Company highlights IM8's rapid traction: $100M ARR in 11 months, October run-rate ~$103M ARR, and 2026 guidance $160–200M. Post-offering liquidity expected at ~$100M cash plus 275 BTC (~$31M), totaling ~$131M.
Prenetics (NASDAQ: PRE) priced a best-efforts public offering to sell 2,992,596 Class A ordinary shares (or pre-funded warrants) together with associated Class A and Class B common warrants at a combined offering price of $16.08 per unit, for expected gross proceeds of approximately $48.0 million before fees and expenses. The Class A warrants carry a $24.12 exercise price and Class B warrants a $32.16 exercise price; each warrant is immediately exercisable and expires five years after issuance.
Proceeds are intended to fund the global expansion of IM8 and the company’s strategic accumulation of Bitcoin (BTC). The offering is expected to close on October 28, 2025, subject to customary closing conditions, with Dominari Securities as placement agent.
Prenetics Global (NASDAQ:PRE) announced on Oct 25, 2025 that it has commenced a public offering of Class A ordinary shares (or prefunded warrants) and common warrants (the "Offering").
The company said net proceeds are intended to fund the global expansion of IM8 and the strategic accumulation of Bitcoin (BTC) as part of a dual health-and-wealth strategy. The Offering is being made from an effective Form F-3 shelf registration declared effective by the SEC on Sept 11, 2025, and is subject to market conditions with no assurance as to completion, size, or terms.
Dominari Securities is acting as sole placement agent; a preliminary prospectus supplement and shelf prospectus will be filed with the SEC and made available to investors.
Prenetics (NASDAQ: PRE) announced on October 8, 2025 the launch of Daily Ultimate Longevity under its IM8 brand. The powder formulation is described as the first supplement to target all 12 hallmarks of aging using a five-complex system with specified clinical ingredient doses (e.g., 3,000 mg glycine, 300 mg NMN, 3 mg spermidine).
IM8 reported rapid scaling from approximately $600k monthly at launch to $6.6M monthly revenue in September 2025 and cites a 2,457% CAGR, targeting $100M ARR within its first year. Product pricing is $149 one-time or $119/month subscription. Prenetics reports >$90M liquid assets (≈$60M cash and 255.4 BTC ≈$31.6M) and says it is debt-free with a path to profitability in early 2026.
Prenetics (NASDAQ: PRE) completed the divestment of ACT for $72 million, receiving $39.9 million in cash upfront and an additional $6.3 million held in escrow payable over 18 months, bringing total transaction proceeds to $46 million. The company says this lifts cash reserves to over $60 million (excluding Bitcoin) and leaves Prenetics debt-free. Prenetics is reallocating resources to its consumer health brand IM8, which is on pace to reach an $100 million ARR within its first 12 months. The company also reports a Bitcoin treasury of 255.4 BTC valued at $31.6 million (investment cost $27.8 million), an unrealized profit of $3.86 million (13.9% return), and a 1 BTC/day purchase policy since August 1, 2025.
Prenetics Global Limited (NASDAQ: PRE), a consumer health sciences company, announced CEO Danny Yeung will deliver a keynote at Token 2049 in Singapore on October 2, 2025. The presentation will focus on IM8, their supplement brand, and their Bitcoin treasury strategy.
The company currently holds 248.42 BTC at an average price of $108,600 per BTC, with a strategy to acquire 1 Bitcoin daily. Their supplement brand IM8 is projected to achieve $100 million in annual recurring revenue within its first year. Prenetics maintains a strong financial position with $63.5 million in current assets, including $46.3 million from ACT Genomics divestment, $17.2 million in cash, and other assets.
FAQ
What is the current stock price of Prenetics (PRE)?
What is the market cap of Prenetics (PRE)?
